Renal dysfunction in acute congestive heart failure: a common problem for cardiologists and nephrologists

Heart Failure Reviews

Volumn 19, Issue 6, 2014, Pages 699-708

  Graziani, Giorgio ^a   Pini, Daniela ^a   Oldani, Silvia ^a   Cucchiari, David ^a   Podestà, Manuel Alfredo ^a   Badalamenti, Salvatore ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

AHF; Cardiorenal syndrome; Diuretic resistance; Ultrafiltration; Vaptans

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; CREATININE; CYSTATIN C; FATTY ACID BINDING PROTEIN; FUROSEMIDE; INTERLEUKIN 18; KIDNEY INJURY MOLECULE 1; LOOP DIURETIC AGENT; MINERALOCORTICOID ANTAGONIST; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; POTASSIUM SPARING DIURETIC AGENT; SODIUM; SPIRONOLACTONE; TOLVAPTAN; TROPONIN I; TROPONIN T; BIOLOGICAL MARKER;

ABLATION THERAPY; ACUTE HEART FAILURE; ACUTE KIDNEY FAILURE; ARTICLE; CARDIOLOGIST; CARDIORENAL SYNDROME; CONTINUOUS INFUSION; COOPERATION; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG MEGADOSE; FATIGUE; GLOMERULUS FILTRATION RATE; HEART DENERVATION; HUMAN; HYPONATREMIA; KIDNEY BLOOD VESSEL; LOW DRUG DOSE; LUNG CONGESTION; MEAN ARTERIAL PRESSURE; MEDICAL DECISION MAKING; MULTICENTER STUDY (TOPIC); NEPHROLOGIST; PATHOPHYSIOLOGY; PATIENT CARE; PATIENT SAFETY; POLYDIPSIA; PRESSORECEPTOR REFLEX; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYMPATHETIC BLOCKING; ULTRAFILTRATION; URINE VOLUME; VAGUS TONE; VASOCONSTRICTION; VENOUS CONGESTION; XEROSTOMIA; ACUTE DISEASE; CARDIO-RENAL SYNDROME; HEART FAILURE;

ACUTE DISEASE; ACUTE KIDNEY INJURY; BIOLOGICAL MARKERS; CARDIO-RENAL SYNDROME; HEART FAILURE; HUMANS;

EID: 84903794699     PISSN: 13824147     EISSN: 15737322     Source Type: Journal    
DOI: 10.1007/s10741-013-9416-5     Document Type: Article

References (88)

1. Nieminen MS, Brutsaert D, Dickstein K et al (2006) EuroHeart Failure Survey II (EHFS II) a survey on hospitalized heart failure patients: description of population. Eur Heart J 27:2725–2736
2. Lloyd-Jones D, Adams R, Carnethon M et al (2009) Heart disease and stroke statistics—2009 update: a report from American Heart Association Statistics Committee and Stroke statistics subcommittee. Circulation 119:e21–e181
3. Adams KF Jr, Fonarow GC, Emerman CL et al (2005) Characteristics and outcomes of patients hospitalized for heart failure in the United States rationale, design and preliminary observation from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 149:209–216
4. Fang J, Mensah GA, Croft JB, Keenan NL (2008) Heart failure-related hospitalization in the US, 1979–2004. J Am Coll Cardiol 52:428–434
5. Ronco C, Haapio M, House AA et al (2008) Cardiorenal syndrome. J Am Coll Cardiol 52:1527–1539
6. Chan EJ, Dellsperger KC (2011) Cardiorenal syndrome: the clinical cardiologists’ perspective. Cardiorenal Med 1:13–22
7. Heywood JT, Fonarow GC, Costanzo MR et al (2007) High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from ADHERE database. J Cardiac Fail 13:422–430
8. Ismail Y, Kasmikha Z, Green HL et al (2012) Cardio-renal syndrome type 1: epidemiology, pathophysiology and treatment. Semin Nephrol 32(1):18–25
9. Cicoira M, Anker SD, Ronco C (2011) Cardio-renal cachexia syndrome (CRCS): pathophysiological foundations of a vicious pathological circle. J Cachexia Sarcopenia Muscle 2(3):135–142
10. Marenzi G, Assanelli E, Campodonico I et al (2010) Acute kidney injury in ST-segment elevation acute myocardial infarction complicated by cardiogenic shock at admission. Crit Care Med 38:438–444
11. Koney M, Karth GD, Geppert A et al (2002) Prognosis of patients who develop acute renal failure during the first 24 hours of cardiogenic shock after myocardial infarction. Am J Med 112:115–119
12. Gheorghiade M, Filippatos SG, De Luca L et al (2006) Congestion in acute heart failure syndrome an essential target of evaluation and treatment. Am J Med 119:S3–S10
13. Chaudry SI, Wang Y, Concato J et al (2007) Patterns of weight change preceding hospitalization for heart failure. Circulation 116:1549–1554
14. Adamson PB, Magalski A, Braunschweig F et al (2003) Ongoing right ventricular hemodynamics in heart failure: clinical value of measurements derived from an implantable monitoring system. J Am Coll Cardiol 41:565–571
15. Cotter G, Metra M, Milo-Cotter O et al (2008) Fluid overload in acute heart failure—re-distribution and other mechanisms beyond fluid accumulation. Eur J Heart Fail 10:165–169
16. Shah SJ, Gheorghiade M (2008) Heart failure with preserved ejection fraction, treat now by treating comorbidities. JAMA 300:431–433
17. Cotter G, Felker GM, Adams KF et al (2008) The pathophysiology of acute heart failure—is it all about fluid accumulation? Am Heart J 155:9–18
18. Gheorghiade M, De Luca F, Fonarow GC (2005) Pathophysiologic targets in the early phase of acute heart failure syndromes. Am J Cardiol 96:11G–17G
19. Flaherty JD, Bax JJ, De Luca L (2009) Acute heart failures syndromes in patients with coronary artery disease: early assessment and treatment. J Am Coll Cardiol 53:254–263
20. Schrier RW, Abraham WT (1999) Hormones and hemodynamics in heart failure. N Engl J Med 341:577–585
21. Gheorghiade M, Filippatos G, Pang PS et al (2008) Changes in clinical, neurohormonal, electrolyte, renal, and hepatic profiles during and after hospitalization for acute decompensated heart failure: analysis from the EVEREST trial (late breaking clinical trial). Paper presented at: European Society of Cardiology, Munich, Germany
22. Cadnapaphorcnai MA, Gurevich AK, Weinberger HD et al (2001) Pathophysiology of sodium and water retention in heart failure. Cardiology 96:122–131
23. Jackson G, Gibbs CR, Davies MK (2000) ABC of heart failure: pathophysiology. Brit Med J 320:167–170
24. McDonough AA (2010) Mechanisms of proximal tubule sodium transport regulation that link extracellular fluid volume and blood pressure. Am J Physiol Regul Integr Comp Physiol 298:R851–R861
25. Schrimpf C, Duffield JS (2011) Mechanisms of fibrosis: the role of the pericyte. Curr Opin Nephrol Hypertens 20:297–305
26. Sharma UC, Pokharel S, van Brakel TJ et al (2004) Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 110:3121–3128
27. Chatterjee K (2005) Neurohormonal activation in congestive heart failure and the role of vasopressin. Am J Cardiol 95:8B–13B
28. Schirer RW (2006) Role of diminished renal function in cardiovascular mortality: marker of pathogenetic factor? J Am Coll Cardiol 47:1–8
29. Aronson D, Burger AJ (2010) The relationship between transient and persistent worsening renal function and mortality in patients with acute decompensated heart failure. J Card Fail 16:541–547
30. Gottlieb SS, Abraham W, Butler J et al (2002) The prognostic importance of different definitions of worsening renal function in congestive heart failure. J Cardiol Fail 8:136–141
31. Weinfeld MS, Chertow GM, Stevenson LW (1999) Aggravated renal dysfunction during intensive therapy for advanced chronic heart failure. Am Heart J 138:285–290
32. Nohria A, Lewis E, Stevenson LW (2002) Medical management of advanced heart failure. JAMA 287:628–640
33. Firth JD, Raine AE, Ledingham JG et al (1988) Raised venous pressure: a direct cause of renal sodium retention in oedema? Lancet 1:1033–1035
34. Ronco C, Cicoira M (2012) Cardiorenal syndrome type 1: pathophysiological crosstalk leading to combined heart and kidney dysfunction in the setting of acutely decompensated heart failure. J Am Coll Cardiol 60(12):1031–1042
35. Severo M, Gaio AR, Lourenço P et al (2012) Diagnostic value of patterns of symptoms and signs of heart failure: application of latent class analysis with concomitant variables in a cross-sectional study. BMJ Open 2(6):e001510
36. McMurray JJ, Adamopoulos S, Anker SD et al (2012) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the heart failure association (HFA) of the ESC. Eur Heart J 33(14):1787–1847
37. Tang WH, Francis GS, Morrow DA et al (2007) National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: clinical utilization of cardiac biomarker testing in heart failure. Circulation 116:e99–e109
38. Chen S (2013) Retooling the creatinine clearance equation to estimate kinetic GFR when the plasma creatinine is changing acutely. J Am Soc Nephrol 24(6):877–878
39. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group (2012) KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl 2:1–138
40. Macdonald J, Marcora S, Jibani M et al (2006) GFR estimation using Cystatin C is not independent of body composition. Am J Kidney Dis 48(5):712–719
41. Harman G, Akbari A, Hiremath S et al (2013) Accuracy of Cystatin C-based estimates of glomerular filtration rate in kidney transplant recipients: a systematic review. Nephrol Dial Transpl 28(3):741–757
42. McCullough PA, Shaw AD, Haase M et al (2013) Diagnosis of acute kidney injury using functional and injury biomarkers: workgroup statements from the tenth acute dialysis quality initiative consensus conference. Contrib Nephrol 182:13–29
43. Felker MG (2011) Loop diuretics in heart failure. Heart Fail Rev 17:305–311
44. Testani JM, Chen J, Mc Cauley BD, Kimmel SE, Sahnnon RP (2010) Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival. Circulation 122:265–272
45. Brater DC (1998) Diuretic therapy. N Engl J Med 339:387–395
46. Felker GM, Lee KL, Bull DA et al (2011) Diuretic strategies in patients with decompensated heart failure. N Engl J Med 364:797–805
47. Felker GM, Mentz RJ (2012) Diuretics and ultrafiltration in acute decompensated heart failure. J Am Coll Cardiol 59:2145–2153
48. Gheorghiade M, Abraham WT, Albert NM et al (2006) Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA 296:2217–2226
49. Sweitzer NK, Lopatin M, Yancy CW et al (2008) Comparison of clinical features and outcome in patients hospitalized with heart failure and normal ejection fraction (> or =55%) versus those with mildly reduced (40 % to 55 %) and moderately to severely reduced (<40%) fractions. Am J Cardiol 101:1151–1156
50. Jourdain P, Jondeau G, Funck F et al (2007) Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter study. J Am Coll Cardiol 49:1733–1739
51. Logeart D, Thabut G, Jourdain P et al (2004) Pre-discharge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J Am Coll Cardiol 43:635–641
52. Paterna S, Fasullo S, Parrinello G et al (2011) Short-term effects of hypertonic saline solution in AHF and long-term effects of a moderate sodium restriction in compensated heart failure with NYHA class III. Am J Med Sci 342:27–37
53. Ellison DH (2001) Diuretic therapy and resistance in congestive heart failure. Cardiology 96:132–143
54. Puscas I, Coltau M, Baican M, Pasca R, Domuta G (1999) The inhibitory effect of diuretics on carbonic anhydrases. Res Commun Mol Pathol Pharmacol 105:213–236
55. Liszkowski M, Nohria A (2010) Rubbing salts into wounds: hypertonic saline to assist with volume removal in heart failure. Curr Heart Fail Rep 7:134–139
56. Arques S, Ambrosi P (2011) Human serum albumin in the clinical syndrome of heart failure. J Cardiac Fail 17:451–458
57. Pitt B, Remme W, Zannad WJ et al (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341:712–717
58. Pitt B et al (2003) Eplerenone, a selective aldosterone blocker in patients with ventricular dysfunction after myocardial infarction. N Engl J Med 348:1309–1321
59. Palmer BF (2004) Managing of hyperkalemia caused by inhibitors of renin–angiotensin–aldosterone system. N Engl J Med 351:585–592
60. Juurlink DN, Mamdani MM, Lee DS et al (2004) Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N Engl J Med 351:543–551
61. Mohammed AA, Van Kimmenade RR, Richards M et al (2010) Hyponatremia, natriuretic peptides, and outcomes in acutely decompensated heart failure: results from the International Collaborative of NT-proBNP Study. Circ Heart Fail 3:354–361
62. Udelson JE, Orlandi C, Ouyang J et al (2008) Acute hemodynamic effects of tolvaptan a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international multicenter, randomized trial. J Am Coll Cardiol 52:1540–1545
63. Rossi J, Bayram M, Udelson JE et al (2007) Improvement in hyponatremia during hospitalisation for worsening heart failure is associated with improved outcome: from acute and chronic therapeutic impact of a vasopressin antagonist in chronic heart failure. Acute Cardiol Care 9:82–86
64. Costello-Boerrighter LC, Smith WB, Boerrighter G et al (2006) Vasopressin-2 receptor antagonism augments water excretion without changes in renal hemodynamic or sodium and potassium excretion in human heart failure. Am J Physiol Renal Physiol 290:F273–F278
65. Berl T, Quintnat-Pellettier F, Verbalis JG et al (2010) Oral Tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol 21:705–712
66. Udelson JE, Mc Grew FA, Flores E et al (2007) Multicenter randomized double-blind placebo-controlled study on the effect of oral tolvaptan on left ventricular dilatation and function in patients with heart failure and systolic dysfunction. J Am Coll Cardiol 49:2151–2159
67. Mebazaa A, Pang PS, Tavares M et al (2010) The impact of early standard therapy on dyspnoea in patients with acute heart failure: the URGENT—dyspnoea study. Eur Heart J 31:832–841
68. Pang PS, Konstam MA, Krasa HB et al (2009) Effects of tolvaptan on dyspnoea relief from the EVEREST trials. Eur Heart J 30:2233–2240
69. Ambrosy A, Goldsmith SR, Gheoghiade M (2011) Tolvaptan for the treatment of heart failure: a review of the literature. Exp Opin Pharmacother 12:961–976
70. Ronco C, Levin NW (2005) Mechanisms of solute transport in extracorporeal therapies. Contrib Nephrol 149:10–17
71. Ronco C, Ricci Z, Bellomo R, Bedogni F (2001) Extracorporeal ultrafiltration for the treatment of overhydration and congestive heart failure. Cardiology 96:155–168
72. Jaski BE, Ha J, Denis BG et al (2003) Peripherally inserted veno-venous ultrafiltration for rapid treatment of volume overloaded patients. J Card Fail 9:227–231
73. Nalesso F, Garzotto F, Ronco C (2012) Technical aspects of extracorporeal ultrafiltration: mechanisms, monitoring and dedicated technology. Contrib Nephrol 164:199–208
74. Marenzi G, Grazi S, Giraldi F et al (1993) Interrelation of humoral factors hemodynamics and fluid and salt metabolism in congestive heart failure: effect of extracorporeal ultrafiltration. Am J Med 94:49–56
75. Costanzo MR, Guglin ME, Saltzberg MT et al (2007) Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 49:675–683
76. Bart BA, Goldsmith SR, Goldsmith MD et al (2012) Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med 367:2296–2304
77. Bradley SM, Levy WC, Veenstra DL et al (2009) Cost-consequence of ultrafiltration for acute heart failure. A decision model analysis. Circ Cardiovasc Qual Outcomes 2:566–573
78. Boyle A, Bank AJ (2005) Ultrafiltration versus usual care for hospitalized patients with heart failure. The relief for acutely fluid-overloaded patients with decompensated congestive heart failure. RAPID CHF Trial J Am Coll Cardiol 46:2043–2046
79. Costanzo MR, Saltzberg MT, Jessup M et al (2010) Ultrafiltration is associated with fewer rehospitalization than continuous diuretic infusion in patients with acute decompensated heart failure: results from UNLOAD. J Cardiol Fail 16:277–284
80. Fiaccadori E, Regolisti G, Maggiore U (2011) Ultrafiltration in heart failure. Am Heart J 161:439–449
81. Conceiao-Souza GE, Pego-Fernandes PM, Cruz F et al (2012) Left cardiac sympathetic denervation for treatment of symptomatic systolic heart failure patients: a pilot study. Eur J heart fail 14:1366–1373
82. Krum H, Schlaich M, Whitbourn R et al (2009) Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 373:1275–1281
83. Krum H, Sobotka P, Mahfoud F et al (2011) Device-based antihypertensive therapy, therapeutic modulation of the autonomic nervous system. Circulation 123:209–215
84. Mahfoud F, Schlaich M, Kindermann I et al (2011) Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation 123(18):1940–1946
85. Davies JE, Manistry CH, Petraco R et al (2013) First-in man safety evaluation of renal denervation for chronic systolic heart failure: primary outcome from REACH-Pilot study. Int J Cardiol 162:189–192
86. Rothstein M (2009) Chronic treatment of resistant hypertension with an implantable device: interim 2 years results of two studies of the Rheos hypertension system. Presented at late breaking clinical trial, Am Coll Cardiol, 30 Mar 2009, Orlando Florida
87. Sanchez LA, Illing K, Levy M (2010) Implantable carotid sinus stimulator for the treatment of resistant hypertension: local effects on carotid artery morphology. Ann Vasc Surg 24:178–184
88. Georgakopoulos D, Little WC, Abraham WT et al (2011) Chronic baroreflex activation: a potential therapeutic approach to heart failure with preserved ejection fraction. J Cardiac Fail 17(2):167–178